Gerald J. Fetterly
- Oncology top 5%
- Cancer Treatment and Pharmacology 18
- Colorectal Cancer Treatments and Studies 13
- Biomaterials top 5%
- Molecular Biology top 10%
- Cancer therapeutics and mechanisms 9
- PI3K/AKT/mTOR signaling in cancer 8
- Cancer Research top 10%
- Pathology and Forensic Medicine top 10%
-
- Lung Cancer Treatments and Mutations 9
-
- Multiple Myeloma Research and Treatments 8
- Acute Myeloid Leukemia Research 8
-
- Hepatocellular Carcinoma Treatment and Prognosis 8
- Co-authors
- Robert M. StraubingerRenuka IyerAmit A. LugadeYasmin ThanavalaJoshua PreyCamille L. BedrosianAnthony W. TolcherAlex A. Adjei
- Partner nations
- United StatesIndiaSweden
In The Last Decade
Gerald J. Fetterly
87 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 99
- Oncology 609
- Biomaterials 264
- Molecular Biology 901
- Cancer Research 188
- Pathology and Forensic Medicine 218
Countries citing papers authored by Gerald J. Fetterly
This map shows the geographic impact of Gerald J. Fetterly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald J. Fetterly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald J. Fetterly more than expected).
Fields of papers citing papers by Gerald J. Fetterly
This network shows the impact of papers produced by Gerald J. Fetterly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald J. Fetterly. The network helps show where Gerald J. Fetterly may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gerald J. Fetterly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 11 | |
| 2 | 2022 | 3 | |
| 3 | 2018 | 72 | |
| 4 | 2017 | 134 | |
| 5 | Determination of optimal dosing of rhIGF-1/rhIGFBP-3 to establish and maintain physiological intrauterine serum IGF-1 levels in preterm infants | 2016 | 1 |
| 6 | 2015 | 14 | |
| 7 | 2014 | 31 | |
| 8 | 2014 | 56 | |
| 9 | 2014 | 38 | |
| 10 | 2014 | 35 | |
| 11 | 2013 | 26 | |
| 12 | 2013 | 12 | |
| 13 | 2013 | 24 | |
| 14 | 2012 | 46 | |
| 15 | 2012 | 1 | |
| 16 | 2012 | 15 | |
| 17 | 2010 | 18 | |
| 18 | 2010 | 131 | |
| 19 | 2008 | 56 | |
| 20 | 2008 | 227 |
About Gerald J. Fetterly
Gerald J. Fetterly is a scholar working on Oncology, Hematology and Hepatology, having authored 88 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (13 papers), Cancer therapeutics and mechanisms (9 papers), Lung Cancer Treatments and Mutations (9 papers), Multiple Myeloma Research and Treatments (8 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Acute Myeloid Leukemia Research (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (8 papers). The work is most often cited by research in Oncology (609 citations), Biomaterials (264 citations) and Molecular Biology (901 citations). Gerald J. Fetterly has collaborated with scholars based in United States, India and Sweden. Frequent co-authors include Robert M. Straubinger, Renuka Iyer, Amit A. Lugade, Yasmin Thanavala, Joshua Prey, Camille L. Bedrosian, Anthony W. Tolcher, Alex A. Adjei, Monica Mita and Grace K. Dy. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.